Tau-targeting therapies for Alzheimer disease

Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study

(2018) Teodoro del Ser et al.   JOURNAL OF ALZHEIMERS DISEASE

Harnessing the Immune System for Treatment and Detection of Tau Pathology

(2018) Erin E. Congdon et al.   JOURNAL OF ALZHEIMERS DISEASE

Vaccination with Sarkosyl Insoluble PHF-Tau Decrease Neurofibrillary Tangles Formation in Aged Tau Transgenic Mouse Model: A Pilot Study

(2018) Kunie Ando et al.   JOURNAL OF ALZHEIMERS DISEASE

AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy

(2017) Christina Ising et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer's disease?

(2017) Lauren S. Whyte et al.   JOURNAL OF NEUROCHEMISTRY

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy

(2017) David R Corey   NATURE NEUROSCIENCE

Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation

(2017) William A. McEwan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

(2017) Kiran Yanamandra et al.   Science Translational Medicine

MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice

(2017) Hayk Davtyan et al.   VACCINE

Membrane association and release of wild-type and pathological tau from organotypic brain slice cultures

(2017) Cara L Croft et al.   Cell Death & Disease

Tau passive immunization inhibits not only tau but also Aβ pathology

(2017) Chun-ling Dai et al.   Alzheimers Research & Therapy

Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage

(2017) Scott S. Shafiei et al.   Frontiers in Aging Neuroscience

Propagation of Tau aggregates

(2017) Michel Goedert et al.   Molecular Brain

Protein misfolding in neurodegenerative diseases: implications and strategies

(2017) Patrick Sweeney et al.   Translational Neurodegeneration

Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies

(2017) Einar M. Sigurdsson   JOURNAL OF ALZHEIMERS DISEASE

Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice

(2017) Hameetha Rajamohamedsait et al.   Scientific Reports

2016 Alzheimer's disease facts and figures

(2016)   Alzheimers & Dementia

Autophagy flux in CA1 neurons of Alzheimer hippocampus: Increased induction overburdens failing lysosomes to propel neuritic dystrophy

(2016) Matteo Bordi et al.   Autophagy

Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau

(2016) Shi-jie Liu et al.   BRAIN

Amyloid-β suppresses AMP-activated protein kinase (AMPK) signaling and contributes to α-synuclein-induced cytotoxicity

(2016) Chih-Li Lin et al.   EXPERIMENTAL NEUROLOGY

Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies

(2016) Nicolas R. Barthélemy et al.   JOURNAL OF ALZHEIMERS DISEASE

Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology

(2016) Rachel H.L.H. Rueli et al.   JOURNAL OF ALZHEIMERS DISEASE

A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer’s Disease

(2016) Charles B. Malpas et al.   JOURNAL OF ALZHEIMERS DISEASE

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

(2016) Ross Penninkilampi et al.   Journal of Neuroimmune Pharmacology

Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice

(2016) Wencheng Liu et al.   JOURNAL OF NEUROSCIENCE

Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity

(2016) Nicolas R Barthélemy et al.   JOURNAL OF PROTEOME RESEARCH

Combination Therapy Showed Limited Superiority Over Monotherapy for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials

(2016) Kelvin K.F. Tsoi et al.   Journal of the American Medical Directors Association

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

(2016) Richard S Finkel et al.   LANCET

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

(2016) Bob Olsson et al.   LANCET NEUROLOGY

A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma

(2016) Jennifer L. McQuade et al.   MELANOMA RESEARCH

Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy

(2016) Erin E. Congdon et al.   Molecular Neurodegeneration

Caspase-2 cleavage of tau reversibly impairs memory

(2016) Xiaohui Zhao et al.   NATURE MEDICINE

Design of the phase II clinical study of the tau vaccine AADvac1 in patients with mild Alzheimer’s disease

(2016) Matej Ondrus et al.   NEUROBIOLOGY OF AGING

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials

(2016) Rik Vandenberghe et al.   Alzheimers Research & Therapy

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement

(2016) Seung-Hye Lee et al.   Cell Reports

Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease

(2016) Francesco Panza et al.   Biomed Research International

The Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer’s Disease and Spinal Cord Injury

(2016) Bing Gong et al.   Frontiers in Molecular Neuroscience

Epidemiological pathology of Tau in the ageing brain: application of staging for neuropil threads (BrainNet Europe protocol) to the MRC cognitive function and ageing brain study

(2016) Stephen B. Wharton et al.   Acta Neuropathologica Communications

Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy

(2016) Antonio Piras et al.   Acta Neuropathologica Communications

Specific Targeting of Tau Oligomers in Htau Mice Prevents Cognitive Impairment and Tau Toxicity Following Injection with Brain-Derived Tau Oligomeric Seeds

(2016) Diana L. Castillo-Carranza et al.   JOURNAL OF ALZHEIMERS DISEASE

The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration

(2015) Jennifer M. Deger et al.   AGING CELL

Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury

(2015) Sandy R. Shultz et al.   BRAIN

Clinical development of curcumin in neurodegenerative disease

(2015) Shuxin Hu et al.   Expert Review of Neurotherapeutics

Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance

(2015) Hilal S. Khalil et al.   JOURNAL OF BIOTECHNOLOGY

Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses

(2015) Anna Wilkaniec et al.   JOURNAL OF NEUROCHEMISTRY

Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD

(2015) Antonella Tramutola et al.   JOURNAL OF NEUROCHEMISTRY

Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells

(2015) M. Usenovic et al.   JOURNAL OF NEUROSCIENCE

The Role of Cdk5 in Alzheimer’s Disease

(2015) Shu-Lei Liu et al.   MOLECULAR NEUROBIOLOGY

Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy

(2015) Asami Kondo et al.   NATURE

Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling

(2015) Natura Myeku et al.   NATURE MEDICINE

Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits

(2015) Sang-Won Min et al.   NATURE MEDICINE

Clinical experiences with systemically administered siRNA-based therapeutics in cancer

(2015) Jonathan E. Zuckerman et al.   NATURE REVIEWS DRUG DISCOVERY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Knocking down disease: a progress report on siRNA therapeutics

(2015) Anders Wittrup et al.   NATURE REVIEWS GENETICS

Tau in physiology and pathology

(2015) Yipeng Wang et al.   NATURE REVIEWS NEUROSCIENCE

Human secreted tau increases amyloid-beta production

(2015) Jessica Bright et al.   NEUROBIOLOGY OF AGING

Tau Immunotherapy

(2015) Einar M. Sigurdsson   Neurodegenerative Diseases

Efficacy and adverse effects of memantine treatment for Alzheimer’s disease from randomized controlled trials

(2015) Jue Jiang et al.   NEUROLOGICAL SCIENCES

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

(2015) Elvira Valera et al.   Neurotherapeutics

A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma

(2015) Deanna Mitchell et al.   PEDIATRIC BLOOD & CANCER

Autophagy in Alzheimer’s disease

(2015) Ameneh Zare-shahabadi et al.   REVIEWS IN THE NEUROSCIENCES

Tau immunotherapy for Alzheimer's disease

(2015) Jan Torleif Pedersen et al.   TRENDS IN MOLECULAR MEDICINE

Truncated tau deregulates synaptic markers in rat model for human tauopathy

(2015) Santosh Jadhav et al.   Frontiers in Cellular Neuroscience

Clinical development of curcumin in neurodegenerative disease

(2015) Shuxin Hu et al.   Expert Review of Neurotherapeutics

Posttranslational modifications of α-tubulin in alzheimer disease

(2015) Fan Zhang et al.   Translational Neurodegeneration

Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies

(2015) Cristina d’Abramo et al.   PLoS One

The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology

(2014) María del Carmen Cárdenas-Aguayo et al.   ACS Chemical Neuroscience

Neuroprotective Effects of Lithium: Implications for the Treatment of Alzheimer’s Disease and Related Neurodegenerative Disorders

(2014) O. V. Forlenza et al.   ACS Chemical Neuroscience

Primary age-related tauopathy (PART): a common pathology associated with human aging

(2014) John F. Crary et al.   ACTA NEUROPATHOLOGICA

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease

(2014) Ludovic Collin et al.   BRAIN

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?

(2014) Francesco Panza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies

(2014) Chun-ling Dai et al.   JOURNAL OF NEURAL TRANSMISSION

Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice

(2014) Arne Ittner et al.   JOURNAL OF NEUROCHEMISTRY

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

(2014) Maj-Linda B Selenica et al.   Journal of Neuroinflammation

Divergent CSF   alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy

(2014) D. Wagshal et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Antibody-Derived In Vivo Imaging of Tau Pathology

(2014) S. Krishnaswamy et al.   JOURNAL OF NEUROSCIENCE

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

(2014) D. L. Castillo-Carranza et al.   JOURNAL OF NEUROSCIENCE

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

(2014) Adam L Boxer et al.   LANCET NEUROLOGY

A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy

(2014) Eduardo Tolosa et al.   MOVEMENT DISORDERS

p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice

(2014) Ken C. Walls et al.   NEUROSCIENCE LETTERS

Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer’s Disease

(2014) Mark E. Gurney et al.   Neurotherapeutics

Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease

(2014) A. M. Fagan et al.   Science Translational Medicine

Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease

(2014) Eva Kontsekova et al.   Alzheimers Research & Therapy

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

(2014) Eva Kontsekova et al.   Alzheimers Research & Therapy

Protein phosphatase 2A dysfunction in Alzheimer’s disease

(2014) Jean-Marie Sontag et al.   Frontiers in Molecular Neuroscience

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes

(2014) Cristian A Lasagna-Reeves et al.   Acta Neuropathologica Communications

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

(2013) Lea Rozenstein-Tsalkovich et al.   EXPERIMENTAL NEUROLOGY

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

(2013) Erin E. Congdon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

(2013) Jiaping Gu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The role of autophagy in neurodegenerative disease

(2013) Ralph A Nixon   NATURE MEDICINE

Alzheimer disease therapy—moving from amyloid-β to tau

(2013) Ezio Giacobini et al.   Nature Reviews Neurology

Prefibrillar Tau Oligomers in Mild Cognitive Impairment and Alzheimer's Disease

(2013) Elliott J. Mufson et al.   Neurodegenerative Diseases

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

(2013) Kiran Yanamandra et al.   NEURON

Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: Focus on davunetide (NAP)

(2013) Iddo Magen et al.   NEUROPEPTIDES

Tau Passive Immunotherapy in Mutant P301L Mice: Antibody Affinity versus Specificity

(2013) Cristina d’Abramo et al.   PLoS One

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

(2013) Clara Theunis et al.   PLoS One

Recent developments of protein kinase inhibitors as potential AD therapeutics

(2013) Volkmar Tell et al.   Frontiers in Cellular Neuroscience

The Importance of Tau Phosphorylation for Neurodegenerative Diseases

(2013) Wendy Noble et al.   Frontiers in Neurology

Deregulated Cdk5 Activity Is Involved in Inducing Alzheimer’s Disease

(2012) Varsha Shukla et al.   ARCHIVES OF MEDICAL RESEARCH

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

(2012) Sara Hall et al.   ARCHIVES OF NEUROLOGY

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

Degradation of tau protein by autophagy and proteasomal pathways: Figure 1

(2012) Yipeng Wang et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

(2012) Nadege Zommer et al.   Current Alzheimer Research

Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β

(2012) Hyejin Park et al.   HUMAN MOLECULAR GENETICS

Tau Oligomers Impair Artificial Membrane Integrity and Cellular Viability

(2012) Katharina Flach et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Trans-cellular Propagation of Tau Aggregation by Fibrillar Species

(2012) Najla Kfoury et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Hyperdynamic Microtubules, Cognitive Deficits, and Pathology Are Improved in Tau Transgenic Mice with Low Doses of the Microtubule-Stabilizing Agent BMS-241027

(2012) D. M. Barten et al.   JOURNAL OF NEUROSCIENCE

The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice

(2012) B. Zhang et al.   JOURNAL OF NEUROSCIENCE

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

(2012) D. P. Fitzgerald et al.   MOLECULAR CANCER THERAPEUTICS

Protein Homeostasis, Aging and Alzheimer’s Disease

(2012) Tobias Morawe et al.   MOLECULAR NEUROBIOLOGY

Mechanisms of Protein Seeding in Neurodegenerative Diseases

(2012) Lary C. Walker et al.   JAMA Neurology

Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer’s mice hippocampus

(2011) Raquel Sanchez-Varo et al.   ACTA NEUROPATHOLOGICA

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

(2011) Orestes V. Forlenza et al.   BRITISH JOURNAL OF PSYCHIATRY

Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib

(2011) Juan Manuel Domínguez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

(2011) Xiyun Chai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

(2011) Allal Boutajangout et al.   JOURNAL OF NEUROCHEMISTRY

Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years

(2011) Heiko Braak et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study

(2011) Melissa E Murray et al.   LANCET NEUROLOGY

Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models

(2011) Nigel C. Jones et al.   NEUROBIOLOGY OF DISEASE

Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease

(2011) B. DaRocha-Souto et al.   NEUROBIOLOGY OF DISEASE

Cell Cycle Activation and Spinal Cord Injury

(2011) Junfang Wu et al.   Neurotherapeutics

Biomarkers in frontotemporal lobar degenerations—Progress and challenges

(2011) William T. Hu et al.   PROGRESS IN NEUROBIOLOGY

Mechanistic Studies of Antibody-Mediated Clearance of Tau Aggregates Using an ex vivo Brain Slice Model

(2011) Pavan K. Krishnamurthy et al.   Frontiers in Psychiatry

Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer’s disease

(2010) Delphine Boche et al.   ACTA NEUROPATHOLOGICA

Neuropathology after active Aβ42 immunotherapy: implications for Alzheimer’s disease pathogenesis

(2010) Delphine Boche et al.   ACTA NEUROPATHOLOGICA

The role of caspases in Alzheimer’s disease; potential novel therapeutic opportunities

(2010) Troy T. Rohn   APOPTOSIS

Tau cleavage and tau aggregation in neurodegenerative disease: Figure 1

(2010) Diane P. Hanger et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Beneficial effect of human anti-amyloid-β active immunization on neurite morphology and tau pathology

(2010) Alberto Serrano-Pozo et al.   BRAIN

REVIEW: Curcumin and Alzheimer's Disease

(2010) Tsuyoshi Hamaguchi et al.   CNS Neuroscience & Therapeutics

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

(2010) Moran Boimel et al.   EXPERIMENTAL NEUROLOGY

Evidence for neuronal expression of functional Fc (ε and γ) receptors

(2010) Hanneke van der Kleij et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer’s disease model

(2010) Niall M. Corcoran et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy

(2010) K. R. Brunden et al.   JOURNAL OF NEUROSCIENCE

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

(2010) A. Boutajangout et al.   JOURNAL OF NEUROSCIENCE

Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

(2010) Lars M. Ittner et al.   NATURE REVIEWS NEUROSCIENCE

Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy

(2010) Sang-Won Min et al.   NEURON

Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models

(2010) J. van Eersel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport: Fig. 1

(2010) Keith A. Vossel et al.   SCIENCE

Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease

(2009) F. Liu et al.   BRAIN

Tau oligomers and aggregation in Alzheimer’s disease

(2009) Marco A. Meraz-Ríos et al.   JOURNAL OF NEUROCHEMISTRY

A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo

(2009) L. Serenó et al.   NEUROBIOLOGY OF DISEASE

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Autophagy Induction and Autophagosome Clearance in Neurons: Relationship to Autophagic Pathology in Alzheimer's Disease

(2008) B. Boland et al.   JOURNAL OF NEUROSCIENCE

Differential Regulation of Dynein and Kinesin Motor Proteins by Tau

(2008) R. Dixit et al.   SCIENCE